Dr Melissa Johnson speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.
The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab vs placebo + atezolizumab in patients with PD-L1-selected NSCLC.
Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
![[UE5] Эффект сонливости. #ue5 #vfx](https://s2.save4k.org/pic/TUd8viidJhM/mqdefault.jpg)
![Explore the Futuristic Sci-Fi Cities of a distant future | Sci-Fi Futuristic Music [AI Generated 21]](https://s2.save4k.org/pic/n8DbBXzeeyw/mqdefault.jpg)
